Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) and DexCom (NASDAQ: DXCM - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability. Volatility and Risk Pacific Biosciences of California
Banque Pictet and Cie SA boosted its holdings in shares of DexCom, Inc. (NASDAQ: DXCM) by 58.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 109,823 shares of the medical device company's stock after purchasing an additional 40,411 shares during the
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.
Beacon Investment Advisory Services Inc. reduced its stake in DexCom, Inc. (NASDAQ: DXCM) by 12.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 272,836 shares of the medical device company's stock after selling 37,468 shares during the period. Beacon Investment
DexCom (NASDAQ: DXCM - Get Free Report) and LENSAR (NASDAQ: LNSR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Volatility and Risk DexCom has a beta of 1.48, suggesting
Sysmex (OTCMKTS:SSMXY - Get Free Report) and DexCom (NASDAQ: DXCM - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership. Profitability This table compares Sysmex and DexCom's net margins, return
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gradient Investments LLC boosted its holdings in DexCom, Inc. (NASDAQ: DXCM) by 13.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 332,006 shares of the medical device company's stock after purchasing an additional 40,343 shares during the period. Gradient Investments LLC owned about
The Touchstone Sands Capital Select Growth Fund (Class A Shares, Load Waived) underperformed its benchmark, the Russell 1000® Growth Index, for the quarter ended December 31, 2025. Security selection weighed on relative performance across all seven sectors in the Fund, with the largest impact from Health Care, Information Technology, and Communication Services. The Fund's results stood in contrast to the broader market, which saw a sharp reversal in high-momentum segments.
DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.
